Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: Opioids are effective for treating acute pain but have safety, tolerability, and addiction concerns while non-opioid analgesics have limited efficacy. Suzetrigine, an oral, non-opioid, small molecule, selectively inhibits the voltage-gated sodium channel 1.8 (Na V 1.8) and has potential to provide efficacious and safe relief for acute pain, without addiction concerns. Methods: To evaluate suzetrigine for treatment of acute pain, we conducted two phase 3, randomized, double-blind, placebo- and active-controlled trials in adults with moderate-to-severe acute pain on the verbal categorical rating scale and ≥4 on the numeric pain rating scale (NPRS) after abdominoplasty (N=1118) or bunionectomy (N=1073). After surgery, participants were randomized to suzetrigine (100mg then 50mg every 12hrs), hydrocodone bitartrate/acetaminophen (HB/APAP; 5/325mg every 6hrs), or placebo for 48 hours. The primary endpoint was time-weighted sum of the pain intensity difference in NPRS from 0-48hrs (SPID48) versus placebo. Key secondary endpoints were SPID48 versus HB/APAP and time to ≥2-point reduction in NPRS from baseline versus placebo. Results: The primary endpoint was achieved in both trials with suzetrigine demonstrating statistically significant and clinically meaningful reduction in pain versus placebo. The least squares mean difference in SPID48 between suzetrigine and placebo was 48.4 (95%CI:33.6,63.1; P <0.0001) after abdominoplasty and 29.3 (95%CI:14.0,44.6; P =0.0002) after bunionectomy. Neither trial achieved the first key secondary endpoint of superiority of suzetrigine versus HB/APAP on SPID48. For the second key secondary endpoint of time to ≥2-point reduction in NPRS, suzetrigine had a more rapid onset of clinically meaningful pain relief versus placebo after abdominoplasty (119min versus 480mins, nominal P<0.0001) and bunionectomy (240mins versus 480mins, nominal P=0.0016). Adverse events (AEs) were similar to those seen in post-surgical settings. Conclusions: As compared with placebo, suzetrigine reduced moderate-to-severe acute pain over 48 hours after abdominoplasty or bunionectomy. Pain reduction with suzetrigine was similar to that with HB/APAP. Suzetrigine was associated with adverse events that were mild to moderate in severity. Clinicaltrials.gov Registration: NCT05558410 and NCT05553366
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
The GTEx Consortium atlas of genetic regulatory effects across human tissues
The GTEx Consortium, Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A., Hadley, K., Handsaker, R. E., Huang, K. H., et al. (2020) · Science · doi:10.1126/science.aaz1776 · Cited by 5,547 · cited 1×
“6 Na V 1.8 is not expressed in the human brain or spinal cord 7–12 ; therefore, suzetrigine should not have the central nervous system side effects associated with nonselective voltage-gated sodium channel blockers or have tolerability and addictive potential associated with centrally acting opioid…”
InfluentialA tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons
Akopian, A. N., Sivilotti, L., & Wood, J. N. (1996) · Nature · doi:10.1038/379257a0 · Cited by 1,103
Myles, P. S., Myles, D. B., Galagher, W., Boyd, D., Chew, C., MacDonald, N., & Dennis, A. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aew466 · Cited by 1,017 · cited 1×
“24,25 The suzetrigine group had rapid time (median time within 1 h) to minimum clinically important pain relief in both abdominoplasty and bunionectomy studies.”
The Role of Voltage-Gated Sodium Channels in Pain Signaling
Bennett, D. L., Clark, A. J., Huang, J., Waxman, S. G., & Dib-Hajj, S. D. (2019) · Physiological Reviews · doi:10.1152/physrev.00052.2017 · Cited by 730
Dworkin, R. H., Turk, D. C., McDermott, M. P., Peirce-Sandner, S., Burke, L. B., Cowan, P., Farrar, J. T., Hertz, S., Raja, S. N., Rappaport, B. A., et al. (2009) · Pain · doi:10.1016/j.pain.2009.08.019 · Cited by 654 · cited 1×
“30 These include the durability of treatment benefit, results of responder analyses, treatment effect compared to available treatments, rapidity of onset, safety and tolerability, patient adherence, and differences in mechanism of action compared to existing treatments.”
Sex differences in pain and analgesia: the role of gonadal hormones
Craft, R. M., Mogil, J. S., & Aloisi, A. M. (2004) · European Journal of Pain · doi:10.1016/j.ejpain.2004.01.003 · Cited by 570 · cited 3×
“The patients enrolled in our studies were representative of the general population who undergo abdominoplasty (96% women) and bunionectomy (86% women) in United States 20,23 and were consistent with previous phase 3 trials of medications approved to treat acute Bertoch et al. 36 We permitted participants to receive re…”
Contribution of Nav1.8 Sodium Channels to Action Potential Electrogenesis in DRG Neurons
Renganathan, M., Cummins, T. R., & Waxman, S. G. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.2.629 · Cited by 566
Olsen, M. F., Bjerre, E., Hansen, M. D., Hilden, J., Landler, N. E., Tendal, B., & Hróbjartsson, A. (2017) · BMC Medicine · doi:10.1186/s12916-016-0775-3 · Cited by 491
Clinically Important Changes in Acute Pain Outcome Measures
Farrar, J. T., Berlin, J. A., & Strom, B. L. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00162-3 · Cited by 459 · cited 2×
“The second key secondary efficacy endpoint was time to 2-point or greater reduction in numeric pain rating scale from baseline ( i.e. , time to clinically meaningful pain relief) 18,19 for suzetrigine compared to placebo.”
Cited by
Suzetrigine: A Novel Non-Opioid Analgesic for Acute Pain Management—A Review
Jones, M., Demery, A., & Al‐Horani, R. A. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4030032 · Cited by 31
Mohiuddin, A. L., & Ahmed, Z. (2025) · Health Science Reports · doi:10.1002/hsr2.71545 · Cited by 10
Beyond Opioids: A Review of Suzetrigine for Acute Pain Management
Pham, A. Q., Yep, H., Wozniak, S., Javvaji, A., Nada, E., & Bergese, S. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209865 · Cited by 10
Pharmacology Update: Suzetrigine: A Novel NaV1.8 Sodium Channel Inhibitor for Acute Pain Management
Peshin, S., Celi, C. V., Rashid, S., Rego, A., & Baumrucker, S. J. (2025) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091251353455 · Cited by 14
(2025) · ASA Monitor · doi:10.1097/01.asm.0001168432.94866.c5 · Cited by 7
Metadata
- Authors
- Bertoch, T., D’Aunno, D., McCoun, J., Solanki, D., Taber, L., Urban, J., Oswald, J., Swisher, M. W., Tian, S., Miao, X., Correll, D. J., Negulescu, P., Bozic, C., & Weiner, S. G.
- Affiliations
- Jean Brown Research (US)
- ERG Clinical, Houston, TX, USA.
- Atlanta Center for Medical Research (US)
- HD Research, LLC, Bellaire, TX, USA.
- Arizona Research Center (US)
- OrthoNebraska, Omaha, NE, USA.
- UC San Diego Health System (US)
- Vertex Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Bozic, Carmen
- ORCID
- Venue
- Anesthesiology
- Published
- 2025-03-21
- Volume
- 142
- Issue
- 6
- Pages
- 1085-1099
- ISSN
- 0003-3022 (ISSN-L)
- 1528-1175
- PMC
- PMC12061372
- OpenAlex
- W4408733249
- Cited by
- 72
- References
- 32
- Citations by year
- 2026: 46 · 2025: 26
- FWCI
- 67.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Anesthesiology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- suzetrigine, voltage-gated sodium channels, non-opioid analgesics, acute pain, postoperative pain, abdominoplasty, bunionectomy, opioid alternatives, pain intensity reduction, analgesic efficacy and safety, postoperative analgesia, postoperative nausea and vomiting, adverse events
- MeSH terms
- Acetaminophen, Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Hydrocodone, Male, Middle Aged, Pain Measurement, Pain, Postoperative, Postoperative Pain, Severity of Illness Index, Treatment Outcome, Analgesics, Non-Narcotic, Young Adult, Acute Pain, Voltage-Gated Sodium Channel Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. https://app.cochat.ai/papers/10.1097/aln.0000000000005460
- The paper
- Bertoch, T., D’Aunno, D., McCoun, J., Solanki, D., Taber, L., Urban, J., Oswald, J., Swisher, M. W., Tian, S., Miao, X., Correll, D. J., Negulescu, P., Bozic, C., & Weiner, S. G. (2025). Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. https://doi.org/10.1097/aln.0000000000005460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.